We identified vincamine, a vasodilator, as a top candidate that significantly counteracts the transcriptional profile of female APOE ε3/ε4 Alzheimer’s disease (AD) patients (Figure 9B). This evidence concerns the gene APOE and early-onset autosomal dominant Alzheimer disease.